NasdaqGS - Nasdaq Real Time Price USD

Embecta Corp. (EMBC)

Compare
15.92 -0.58 (-3.52%)
As of 11:43 AM EDT. Market Open.
Loading Chart for EMBC
DELL
  • Previous Close 16.50
  • Open 16.44
  • Bid 15.81 x 100
  • Ask 16.03 x 100
  • Day's Range 15.92 - 16.61
  • 52 Week Range 9.93 - 19.79
  • Volume 75,365
  • Avg. Volume 418,654
  • Market Cap (intraday) 918.613M
  • Beta (5Y Monthly) 0.96
  • PE Ratio (TTM) 13.27
  • EPS (TTM) 1.20
  • Earnings Date Nov 19, 2024 - Nov 25, 2024
  • Forward Dividend & Yield 0.60 (3.64%)
  • Ex-Dividend Date Aug 27, 2024
  • 1y Target Est 16.07

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

www.embecta.com

2,200

Full Time Employees

September 30

Fiscal Year Ends

Recent News: EMBC

View More

Performance Overview: EMBC

Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EMBC
13.11%
S&P 500
17.90%

1-Year Return

EMBC
1.80%
S&P 500
26.36%

3-Year Return

EMBC
66.83%
S&P 500
24.65%

5-Year Return

EMBC
66.83%
S&P 500
24.65%

Compare To: EMBC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EMBC

View More

Valuation Measures

Annual
As of 9/17/2024
  • Market Cap

    952.08M

  • Enterprise Value

    2.31B

  • Trailing P/E

    13.75

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.86

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.07

  • Enterprise Value/EBITDA

    11.17

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.23%

  • Return on Assets (ttm)

    9.64%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.12B

  • Net Income Avi to Common (ttm)

    69.7M

  • Diluted EPS (ttm)

    1.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    275.1M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    46.59M

Research Analysis: EMBC

View More

Company Insights: EMBC

Research Reports: EMBC

View More

People Also Watch